The serum levels of the cytokines involved in the Th17 and Th1 cell commitment are increased in individuals with borderline thrombocytopenia

According to the International Working Group consensus panel [1], primary Immune Thrombocytopenia (ITP) is defined as a peripheral blood platelet count less than 100 × 10⁹/L in the absence of any obvious cause of thrombocytopenia. The recommendation of this value as the threshold for diagnosis of ITP, instead of the historical criteria of 150 × 10⁹/L, was first proposed by Rodeghiero et al.[2] based on the results of Stasi et al.[3] showing that healthy individuals with incidentally discovered platelet count between 100 and 150 × 10⁹/L have a 10-year probability of developing persistent thrombocytopenia of only 6.9% and of developing autoimmune disorders other than ITP of 12%. However, in addition to the fact that this criterion has not been formally validated yet [4], patients with platelet count between 100 and 150 × 10⁹/L remain without a diagnosis [5]. Recently, our group evaluated the serum cytokine profile of 98 patients with chronic ITP (platelet less than 100 × 10⁹/L) [6] attending the University Hospital, Universidade Federal de Minas Gerais, Brazil and demonstrated higher levels of Th17 cell-related cytokines, in addition to Th1-associated cytokines in the patients than in blood donor controls. We have also demonstrated [7] that IL1RN VNTR and IL2- 330 allele polymorphisms were associated with increased concentrations of IL-1β and of IL-2, respectively and were risk factors for chronic ITP. In this study, we compared serum Th1 and Th17 cytokine profile of 28 individuals (13 female and 15 male, mean age 49.2 years, range from 19 to 79 years) with persistent borderline thrombocytopenia with that of chronic ITP patients and controls we have previously evaluated [6]. None of the included individuals had obvious predisposing conditions or factors associated with thrombocytopenia. The platelet count of the subjects ranged from 101 to 138 × 10⁹/L with a mean (±SD) of 120(±10) × 10⁹/L and the duration of the thrombocytopenia varied from one to 12 years with a mean (±SD) of 4.7(±3.6) years. The serum cytokine concentrations (picogram per milliliter, pg/mL) were assayed in duplicate by ELISA (Biosource, Camarillo, CA). This study was approved by the Ethics Committee of the Institution and informed consent was obtained from all subjects. Data were analyzed with SPSS software package version 17.0 (SPSS Inc., Chicago, IL) and as the data showed significant departures from normality even after log transformation, comparisons among the groups were done by the two-tailed Mann-Whitney U-test. The level of significance was set at p ≤ 0.05.

Of note, the cytokine profile of the studied individuals with platelet count between 100 and 150 × 10⁹/L did not differ from that of ITP patients we have previously studied [6] (IL-17A: 165.0 vs. 169.0 pg/mL, p = 0.55; IL-1β: 2.9 vs. 3.5 pg/mL, p = 0.40; IL-6: 11.9 vs. 14.0 pg/mL, p = 0.32; IL-23: 22.6 vs. 17.7 pg/mL, p = 0.10; IL-2: 18.7 vs. 17.3 pg/mL, p = 0.71; IFN-γ: 23.4 vs. 24.7 pg/mL, p = 0.84; and IL-12p70: 9.0 vs. 7.3 pg/mL, p = 0.46, respectively), but was significantly different from the cytokine profile observed in the healthy blood donors (Figure 1). A 6.3-fold increased serum level of IL-17A, the signature pro-inflammatory cytokine of the Th17 cell, and a 2.5-, 5.0-, and 85.6-fold increased of IL-1β, IL-6 and IL-23, Th17-associated cytokines (p < 10^-3 for all) were observed in the studied group when compared with the control group (Figure 1). Upregulation of the Th1 cytokines characterized by increased levels of IL-2 (6.3-fold increased, p < 10^-3), IL-12 p70 (31.0-fold increased, p < 10^-3) and IFN-γ (2.8-fold increased, p = 0.001) were also observed (Figure 1). Also, the patients with ITP and individuals with platelet count between 100 and 150 × 10⁹/L did not differ in respect to the mean age (p = 0.32), gender (p = 0.20) and duration of thrombocytopenia (p = 0.82). Here we also reanalyzed the data of cytokine gene polymorphisms of 122 patients with platelet count bellow 150 × 10⁹/L published elsewhere [7] by stratifying the group into those with platelet count less than 100 × 10⁹/L and those with platelets between 100 and 150 × 10⁹/L. The presence of at least one allele 2 of IL1RN and one G polymorphic allele of IL2-330 was more frequently observed in the group of subjects with platelet count between 100 and 150 × 10⁹/L (p = 0.04 and p = 0.03, respectively) than in the controls, as well as in the patients with platelets less than 100 × 10⁹/L (p = 0.007 and p = 0.02, respectively) than in the controls, but they did not differ between the patient groups (p = 0.8 and p = 0.7 for IL1RN and IL2 polymorphisms, respectively). The polymorphisms were associated with enhanced concentration of IL-1β (6.3 vs. 2.5 pg/mL, p = 0.002) and IL-2 (22.8 vs. 14.9 pg/mL, p = 0.02) in the IL1RN*2 and IL2-330G carriers, respectively, in the group of subjects with platelet count between 100 and 150 × 10⁹/L. Also, in the patients with platelet count less than 100 × 10⁹/L, increased serum concentrations of IL-1β (6.3 vs. 2.8 pg/mL, p < 10^-3) and IL-2 (22.6 vs. 14.8 pg/mL, p < 10^-2) were observed in the carriers of IL1RN*2 and IL2-330G polymorphic alleles, respectively. In conclusion, individuals with platelet count between 100 and 150 × 10⁹/L have enhanced levels of proinflammatory cytokines linked to Th1 and Th17 cell response, and are more frequently carriers of polymorphisms in genes that encode cytokines involved in the commitment of Th1 and Th17 immune response, similarly to that observed in patients with chronic ITP, which points to the need of a careful follow-up of this group of individuals and to search for pathogenic mechanisms associated with this condition.